Irbesartan/Hydrochlorothiazide Arrow

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartan/Hydrochlorothiazide Arrow, is an angiotensin II receptor blocker / thiazide diuretic presented as a tablet for oral use. It treats hypertension in adult patients, helping to lower elevated blood pressure when lifestyle measures alone are inadequate and when combination therapy is required.

GNH USA supplies Irbesartan/Hydrochlorothiazide Arrow as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics worldwide through regulated channels, ensuring quality, traceability, and adherence to local regulatory requirements.

Irbesartan/Hydrochlorothiazide is used in the management of hypertension, a condition characterized by elevated arterial pressure. - Essential hypertension: lowers both systolic and diastolic blood pressure in patients with primary hypertension. - Secondary hypertension (e.g., renal‑related): assists in controlling blood pressure when hypertension is due to underlying kidney disease. - Hypertension requiring combination therapy: provides added blood pressure reduction when monotherapy does not achieve target levels.

The most frequently reported adverse reactions with Irbesartan/Hydrochlorothiazide involve the cardiovascular, metabolic and renal systems.

Common Side Effects: - Dizziness: light‑headed sensation, especially after the first dose. - Headache: mild to moderate intensity. - Increased urination: due to the diuretic component. - Electrolyte disturbances (e.g., low potassium): mild changes in blood electrolyte levels.

Serious or Rare Side Effects: - Severe dehydration: marked fluid loss requiring medical attention. - Acute kidney injury: sudden decline in renal function. - Hyperkalemia: elevated potassium levels, potentially life‑threatening. - Allergic reactions: rash, itching, or swelling of the face and throat.

Before initiating therapy with Irbesartan/Hydrochlorothiazide, clinicians should consider several safety measures. - Blood pressure monitoring: ensure adequate control and avoid hypotension. - Renal function assessment: evaluate serum creatinine and eGFR prior to use. - Electrolyte surveillance: check potassium and sodium levels regularly. - Pregnancy and lactation: avoid use unless benefits outweigh risks, as safety data are limited. - Drug interactions: review concomitant medications for potential additive effects. - Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use can increase risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: thiazide component can raise lithium concentrations, risking toxicity. - ACE inhibitors or other ARBs: additive effects on blood pressure and potassium levels. - NSAIDs (high dose, chronic): can reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives (beta‑blockers, calcium channel blockers): may enhance blood pressure lowering, requiring dose adjustment. - CYP450 inhibitors (e.g., fluconazole): can increase irbesartan plasma levels. - Antidiabetic agents: diuretic‑induced changes in glucose may affect glycemic control. - NSAIDs (short‑term, low dose): may modestly affect renal handling of electrolytes.